Antibody Drug Conjugate (ADC)

Antibody Drug Conjugate (ADC) represents a sophisticated therapeutic modality combining the targeting specificity of monoclonal antibodies with the potent cytotoxic effects of small molecule drugs through chemical linker technology. This precision medicine approach enables selective delivery of highly toxic payloads directly to diseased cells, particularly cancer cells expressing specific surface antigens, while sparing healthy tissues from systemic exposure. The ADC architecture comprises three critical components: the antibody targeting moiety, the cytotoxic payload, and the linker chemistry connecting them, each requiring careful optimisation.

The ADC market has experienced remarkable growth, with multiple approved products transforming oncology treatment paradigms and robust pipelines addressing diverse solid tumours and haematological malignancies. Development challenges include achieving optimal drug to antibody ratios, selecting appropriate linker stability profiles, managing payload potency and toxicity, and controlling product heterogeneity during manufacturing. Companies employ advanced bioconjugation technologies including site specific conjugation, click chemistry, and engineered cysteine residues to produce homogeneous ADCs with improved therapeutic indices. Manufacturing ADCs demands specialised facilities, rigorous analytical characterisation using techniques like hydrophobic interaction chromatography and mass spectrometry, and stringent quality controls. The competitive landscape includes established pharmaceutical leaders and specialised biotechnology companies developing novel linker payloads, alternative conjugation platforms, and next generation formats. As the field matures, focus shifts toward expanding target selection, improving linker bystander effects, and combining ADCs with immunotherapies to maximise clinical benefit while navigating complex regulatory pathways and manufacturing scale up challenges.